HER2-targeted therapies: how far we've come--and where we're headed
Davidson, N.E.
Oncology 25(5): 425-426
2011
ISSN/ISBN: 0890-9091 PMID: 21710840 Document Number: 650761
Document emailed within 1 workday
Related Documents
McKay, M. 2008: Targeted therapies for cancer Australian Family Physician 37(4): 201Sablin, M.-P.; Dreyer, C.; Colichi, C.él.; Bouattour, M.; Faivre, S. 2010: Targeted therapies in colorectal cancer La Revue du Praticien 60(8): 1094-1099
Collignon, J.; Jerusalem, G. 2012: Will targeted therapies replace chemotherapy? Revue Medicale de Liege 67(Special Issue): 29-36
Ali, R.; Graves, E.E. 2013: Targeted therapies and hypoxia imaging Quarterly Journal of Nuclear Medicine and Molecular Imaging: Official Publication of the Italian Association of Nuclear Medicine and the International Association of Radiopharmacology and Section of the Society Of. 57(3): 283-295
Abdulrahman Jnr, G.O. 2015: Targeted therapies in the management of breast cancer Gulf Journal of Oncology 1(19): 38-43
Kavanaugh, A.F. 2006: B cell targeted therapies: safety considerations Journal of Rheumatology. Supplement 77: 18-23
Gerber, D.E. 2008: Targeted therapies: a new generation of cancer treatments American Family Physician 77(3): 311-319
Janjigian, Y.Y.; Shah, M.A. 2011: Molecularly targeted therapies in advanced gastric cancer Minerva Gastroenterologica E Dietologica 57(1): 75-88
Del Rivero, J.; Kohn, E.C. 2017: PARP Inhibitors: the Cornerstone of DNA Repair-Targeted Therapies Oncology 31(4): 265-273
Verset, G.; Borbath, I.; Delaunoit, T.; Demetter, P.; Demolin, G.; Hendlisz, A.; Pattyn, P.; Pauwels, S.; Peeters, M.; Roeyen, G.; Van Cutsem, E.; Van Hootegem, P.; Verslype, C.; Van Laethem, J.L. 2009: The potential role of targeted therapies in the management of neuroendocrine tumours Acta Gastro-Enterologica Belgica 72(1): 59-62
Gennigens, C.; Sautois, B.; Rorive, A.; Fillet, G.; Jerusalem, G. 2007: Current therapeutic progress in oncology: the development of targeted therapies Revue Medicale de Liege 62(5-6): 391-398
Grothey, A. 2006: Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer Oncology 20(14 Suppl 10: 21-28
Quatresooz, P.; Rorive, A.; Paquet, P.; Piérard-Franchimont, C.; Piérard, G.E. 2009: Cutaneous adverse effects predicting the efficacy of targeted antineoplastic therapies Revue Medicale de Liege 64(5-6): 347-350
Moro-Sibilot, D.; Coudurier, M. 2009: Targeted therapies in second line treatment of metastatic non-small cell lung cancer La Revue du Praticien 59(7): 955-956
Tonra, J.R.; Corcoran, E.; Deevi, D.S.; Steiner, P.; Kearney, J.; Li, H.; Ludwig, D.L.; Zhu, Z.; Witte, L.; Surguladze, D.; Hicklin, D.J. 2009: Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models Anticancer Research 29(6): 1999-2007
Keir, G.John.; Walsh, S.L.F.; Gatzoulis, M.A.; Marino, P.S.; Dimopoulos, K.; Alonso, R.; Raposeiras-Roubin, S.; Renzoni, E.A.; Maher, T.M.; Wells, A.U.; Wort, S.John. 2014: Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies Sarcoidosis Vasculitis and Diffuse Lung Diseases: Official Journal of Wasog 31(2): 82-90
Boniface Ngah Epo; Francis Menjo Baye, 2016: Decomposing Poverty-Inequality Linkages of Sources of Deprivation by Men-Headed and Women-Headed Households in Cameroon Journal of Economic Development 41(1): 57-79
Boniface Ngah Epo; Francis Menjo Baye, 2016: Decomposing Poverty-Inequality Linkages of Sources of Deprivation by Men-Headed and Women-Headed Households in Cameroon Journal of Economic Development 41(1): 57-79
Duchemann, B.; Zelek, L. 2017: Cancer treatment. Surgery, radiotherapy, medical treatments (chemotherapy, targeted therapies, immunotherapy). Multidisciplinary therapeutic decision and patient information La Revue du Praticien 67(10): E499-E509
Weinberg, J.M.; Bottino, C.J.; Lindholm, J.; Buchholz, R. 2005: Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept Journal of Drugs in Dermatology: Jdd 4(5): 544-555